- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pfizer Inc (PFE)
Find all the information about Pfizer shares. Discover our multiple sections with data on PFE Pfizer share price, intuitive charts, historical data, technical analysis, latest news on Pfizer stock and more. Find quotes of PFE in the main stock markets such as NYSE and Mexico, among others.
NYSE
Currency in USD
24.03
+0.06(+0.25%)
Closed·
Pre Market
24.15+0.12(+0.50%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
23.77
24.09
52 wk Range
20.92
31.54
PFE Scorecard
Full Analysis
High shareholder yield
High dividend Yield
More Info
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
23.7724.09
52 wk Range
20.9231.54
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(7.16%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(7.16%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PFE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
29.24
Upside
+21.68%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 14 consecutive years
Pfizer Inc Company Profile
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer Inc SWOT Analysis
Strategic Maneuvers | Explore Pfizer's bold $1.25 billion acquisition of SSGJ-707, a VEGFxPD-1 bispecific antibody, signaling its commitment to oncology expansion |
Financial Resilience | Delve into Pfizer's robust financial performance, with 2024 revenues reaching $63.6 billion and EPS exceeding expectations at $3.11 |
Pipeline Potential | Discover ponsegromab, Pfizer's promising GDF-15 inhibitor for cancer cachexia, representing a multi-billion dollar opportunity in an untapped market |
Market Outlook | Analyst price targets range from $24 to $45, reflecting varied perspectives on Pfizer's growth potential amid upcoming patent expirations and strategic initiatives |
Pfizer Inc Earnings Call Summary for Q1/2025
- Pfizer Q1 2025 EPS of $0.92 beat $0.68 forecast; revenue of $13.7B missed expectations; stock rose 3.75% pre-market
- Revenue declined 6% operationally; company returned $2.4B to shareholders via dividends; adjusted gross margin ~81%
- Full-year 2025 guidance: revenue $61-64B, adjusted EPS $2.80-$3.00; trending towards upper end of EPS range
- Focus on growth areas: oncology, vaccines, internal medicine; cost realignment and manufacturing optimization ongoing
- Risks include Medicare Part D redesign, potential tariff impacts, sector competition, and maintaining market leadership
Last Updated: 30/04/2025, 01:46 am
Read Full TranscriptCompare PFE to Peers and Sector
Metrics to compare | PFE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPFEPeersSector | |
|---|---|---|---|---|
P/E Ratio | 17.4x | −1.1x | −0.5x | |
PEG Ratio | 0.01 | −0.02 | 0.00 | |
Price/Book | 1.5x | 2.6x | 2.6x | |
Price / LTM Sales | 2.2x | 7.1x | 3.0x | |
Upside (Analyst Target) | 17.3% | 195.6% | 52.5% | |
Fair Value Upside | Unlock | 5.5% | 8.7% | Unlock |
Analyst Ratings
9 Buy
15 Hold
1 Sell
Ratings:
25 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 29.24
(+21.68% Upside)
Earnings
Latest Release
Apr 29, 2025
EPS / Forecast
0.92 / 0.68
Revenue / Forecast
13.72B / 14.09B
People Also Watch
FAQ
What Is the Pfizer (PFE) Stock Price Today?
The Pfizer stock price today is 24.03
What Stock Exchange Does Pfizer Trade On?
Pfizer is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for Pfizer?
The stock symbol for Pfizer is "PFE."
Does Pfizer Pay Dividends? What’s The Current Dividend Yield?
The Pfizer dividend yield is 7.16%.
What Is the Pfizer Market Cap?
As of today, Pfizer market cap is 136.62B.
What Is Pfizer's Earnings Per Share (TTM)?
The Pfizer EPS (TTM) is 1.39.
When Is the Next Pfizer Earnings Date?
Pfizer will release its next earnings report on 04 Aug 2025.
From a Technical Analysis Perspective, Is PFE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Pfizer Stock Split?
Pfizer has split 6 times.
How Many Employees Does Pfizer Have?
Pfizer has 81000 employees.
What is the current trading status of Pfizer (PFE)?
As of 24 June 2025, Pfizer (PFE) is trading at a price of 24.03, with a previous close of 24.03. The stock has fluctuated within a day range of 23.77 to 24.09, while its 52-week range spans from 20.92 to 31.54.
What Is Pfizer (PFE) Price Target According to Analysts?
The average 12-month price target for Pfizer is USD29.2387, with a high estimate of USD42 and a low estimate of USD23. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +21.68% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.